Metformin synergistically enhances the antitumor activity of the third-generation EGFR-TKI CO-1686 in lung cancer cells through suppressing NF-κB signaling.
Yong-Hong PanCai-Yu LinCong-Hua LuLi LiYu-Bo WangHeng-Yi ChenYong HePublished in: The clinical respiratory journal (2018)
NF-κB signaling activation induced acquired resistance to CO-1686. Metformin sensitized resistant cells to CO-1686 via inhibiting NF-κB signaling.